A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1
Public ClinicalTrials.gov record NCT03743051. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial was to compare the efficacy and safety of anamorelin HCl (the investigational drug) to that of placebo (tablet with no drug) in patients with advanced non-small cell lung cancer and cachexia (cancer-related weight loss). The main question it aimed to answer was as follows: Do patients who receive anamorelin HCl gain more body weight and show more improvement in anorexia symptoms than those who receive placebo. Approximately 316 patients were to be enrolled in the study. Of these patients, an equal number were to be assigned to each treatment group (anamorelin HCl or placebo). Participants were to take their assigned study drug by mouth once daily for a total of 24 weeks. During this treatment period, the patients were to visit the clinical study site every 3 weeks for health and other study-related assessments. Two weeks after the last treatment, patients were to receive a follow-up phone call.
Study identification
- NCT ID
- NCT03743051
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 318 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2019 (Actual)
- Primary completion
- Feb 11, 2023 (Actual)
- Completion
- Feb 11, 2023 (Actual)
- Last update posted
- Oct 6, 2026
2019 – 2023
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Chen | Tucson | Arizona | 85745 | — |
| CARTI Cancer Center | Little Rock | Arkansas | 72205 | — |
| The Oncology Insitute of Hope and Innovation | Riverside | California | 92506 | — |
| Hartford HealthCare Cancer Institute at the Hospital of Central Connecticut | Plainville | Connecticut | 06062 | — |
| 21st Century Oncology | Jacksonville | Florida | 32204 | — |
| Mid Florida Hematology and Oncology Center | Orange City | Florida | 32763 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Joliet Oncology Hematology Associates, Ltd | Joliet | Illinois | 60435 | — |
| Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| McFarland Clinic, PC | Ames | Iowa | 50010 | — |
| MercyOne Waterloo Cancer Center | Waterloo | Iowa | 50702 | — |
| Jackson Oncology Associates, PLC | Jackson | Minnesota | 39216 | — |
| Trinitas Comprehensive Cancer Center/Trinitas Regional Medical Center | Elizabeth | New Jersey | 07207 | — |
| Englewood Health | Englewood | New Jersey | 07631 | — |
| Broome Oncology LLC | Johnson City | New York | 13790 | — |
| Northwell Health | Lake Success | New York | 11042 | — |
| Stony Brook Cancer Center | Stony Brook | New York | 11794 | — |
| Ohio State University Wexner Medical Center The James Cancer Hospital and Solove Research Institute | Columbus | Ohio | 43210 | — |
| Gettysburg Cancer Center | Gettysburg | Pennsylvania | 17325 | — |
| Tennessee Cancer Specialist | Knoxville | Tennessee | 37909 | — |
| Community Cancer Trial of Utah | Ogden | Utah | 84405 | — |
| Virginia Commonwealth University, Massey Cancer Center | Richmond | Virginia | 23298-0230 | — |
| Kadlec Clinic Hematology and Oncology | Kennewick | Washington | 99336 | — |
| Wenatchee Valley Hospital & Clinics | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03743051, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03743051 live on ClinicalTrials.gov.